Pfizer Inc
NYSE: PFE
$29.52
+$0.21 (+0.7%)
Closing Price on September 24, 2024
PFE Articles
Merck shares posted a new 52-week high last Tuesday and closed Friday less than a buck from that high. Year to date, Its shares are up 11%.
Published:
Last Updated:
thinkstockJanuary 13, 2015: Markets opened higher again on Tuesday but stocks drifted lower all day and finally broke through into the read by mid-afternoon. Oil had another up and down day, closing...
Published:
Last Updated:
One key consideration for the year ahead is that the Pfizer of 2016 or 2017 is likely to be night and day different from the Pfizer of 2005.
Published:
One key consideration for the year ahead is that Johnson & Johnson raised its dividends again and managed to have upside performance above what was expected.
Published:
thinkstockDecember 26, 2014: Markets opened higher on Friday on a morning when it was difficult to find any market-moving news at all. Energy opened higher but traded about $1 a barrel lower (down...
Published:
Last Updated:
With investors loving dividends so much, 24/7 always tries to take a look at what the Dogs of the Dow will look like for the year ahead.
Published:
While this was generally a known event coming down the pipe, arthritis drug Celebrex now has a generic competitor in America.
Published:
thinkstockDecember 4, 2014: Markets opened higher on Friday after the federal government released a better-than-expected report on employment. Job gains rose to their highest level since 2012, and...
Published:
Last Updated:
The U.S. equity market is still a great place to be, and the analysts at Jefferies may have a good plan for where to rotate some 2014 winners and losers.
Published:
A new report from Jefferies focuses on four stocks to buy that have impending events that could make a difference for investors.
Published:
thinkstockNovember 25, 2014: Markets opened higher on Tuesday but the gains were small heading into the long weekend. The second reading on U.S. GDP was higher than expected, but that was not enough...
Published:
Last Updated:
For the third consecutive year, the company spending the most on research and development (R&D) was Germany's Volkswagen.
Published:
Last Updated:
Durect and Pain Therapeutics have been stung by Pfizer's decision to discontinue to develop Remoxy.
Published:
thinkstockOctober 24, 2014: Markets opened slightly higher on Friday, and following a short trip below the break-even line, marched higher and appear headed to close up for the second consecutive...
Published:
Last Updated:
Pfizer's new buyback is simply too large and too significant to ignore, and it might jokingly be called "on Viagra."
Published: